Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01370811 · ClinicalTrials.gov registry record · Phase 2
A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease
A Phase 2 study of Sialorrhoea, sponsored by Orient Pharma Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01370811 is a Phase 2 study of Sialorrhoea that has completed, run by Orient Pharma Co.. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01370811, a Phase 2 study of Sialorrhoea, has completed, sponsored by Orient Pharma Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether OC (oxybutynin and clonidine) oral solution is effective in reducing saliva secretion in patients suffering from Parkinson's Disease with excessive salivation.
Conditions Studied
Interventions
- DRUG oxybutynin and clonidine oral solution treatment A
- DRUG oxybutynin and clonidine oral solution treatment B
- DRUG oxybutynin and clonidine oral solution treatment C
- DRUG oxybutynin and clonidine oral solution treatment D
Study Locations (1)
Michigan
- QUEST Research Institute - Bingham Farms
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01370811
The ClinicalTrials.gov registry entry for NCT01370811 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orient Pharma Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sialorrhoea appearing as the primary indexed condition, and to 4 interventions - of which oxybutynin and clonidine oral solution treatment A is the first listed.
NCT01370811 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT01370811 about?
NCT01370811 is a clinical study titled "A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease". The purpose of this study is to determine whether OC (oxybutynin and clonidine) oral solution is effective in reducing saliva secretion in patients suffering from Parkinson's Disease with excessive salivation.
What is the current status of trial NCT01370811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2011-08. Estimated completion is 2012-09.
What conditions does trial NCT01370811 study?
This clinical trial studies the following conditions: Sialorrhoea.
What interventions are being tested in trial NCT01370811?
The interventions under investigation include: oxybutynin and clonidine oral solution treatment A (DRUG), oxybutynin and clonidine oral solution treatment B (DRUG), oxybutynin and clonidine oral solution treatment C (DRUG), oxybutynin and clonidine oral solution treatment D (DRUG).
Who is sponsoring clinical trial NCT01370811?
This trial is sponsored by Orient Pharma Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01370811 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.